{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:19:46Z","timestamp":1793859586157,"version":"4.6.1"},"reference-count":186,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271447"],"award-info":[{"award-number":["82271447"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["823B2026"],"award-info":[{"award-number":["823B2026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Innovative Research Groups of Hubei Province","award":["2022CFA026"],"award-info":[{"award-number":["2022CFA026"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2019YFE0115900"],"award-info":[{"award-number":["2019YFE0115900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Project for Academic and Technical Leaders of Major Disciplines in Jiangxi Province","award":["20213BCJL22049"],"award-info":[{"award-number":["20213BCJL22049"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00018-024-05419-5","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T22:02:13Z","timestamp":1725314533000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Lysosomal dysfunction in \u03b1-synuclein pathology: molecular mechanisms and therapeutic strategies"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1851-9380","authenticated-orcid":false,"given":"Lijun","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6708-1472","authenticated-orcid":false,"given":"Zhentao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"5419_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386:896\u2013912. https:\/\/doi.org\/10.1016\/S0140-6736(14)61393-3","journal-title":"Lancet"},{"key":"5419_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-021-00098-4","author":"Y Aman","year":"2021","unstructured":"Aman Y, Schmauck-Medina T, Hansen M et al (2021) Autophagy in healthy aging and disease. Nat Aging. https:\/\/doi.org\/10.1038\/s43587-021-00098-4","journal-title":"Nat Aging"},{"key":"5419_CR3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00401-021-02266-7","volume":"141","author":"D Erskine","year":"2021","unstructured":"Erskine D, Koss D, Korolchuk VI et al (2021) Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders. Acta Neuropathol 141:511\u2013526. https:\/\/doi.org\/10.1007\/s00401-021-02266-7","journal-title":"Acta Neuropathol"},{"key":"5419_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.tins.2021.12.004","volume":"45","author":"V Udayar","year":"2022","unstructured":"Udayar V, Chen Y, Sidransky E, Jagasia R (2022) Lysosomal dysfunction in neurodegeneration: emerging concepts and methods. Trends Neurosci 45:184\u2013199. https:\/\/doi.org\/10.1016\/j.tins.2021.12.004","journal-title":"Trends Neurosci"},{"key":"5419_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41556-018-0244-7","volume":"21","author":"RE Lawrence","year":"2019","unstructured":"Lawrence RE, Zoncu R (2019) The lysosome as a cellular centre for signalling, metabolism and quality control. Nat Cell Biol 21:133\u2013142. https:\/\/doi.org\/10.1038\/s41556-018-0244-7","journal-title":"Nat Cell Biol"},{"key":"5419_CR6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.tins.2019.10.002","volume":"42","author":"RL Wallings","year":"2019","unstructured":"Wallings RL, Humble SW, Ward ME, Wade-Martins R (2019) Lysosomal dysfunction at the centre of Parkinson\u2019s disease and frontotemporal dementia\/amyotrophic lateral sclerosis. Trends Neurosci 42:899\u2013912. https:\/\/doi.org\/10.1016\/j.tins.2019.10.002","journal-title":"Trends Neurosci"},{"key":"5419_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Gaetani L, Eusebi P et al (2019) CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol 18:573\u2013586. https:\/\/doi.org\/10.1016\/S1474-4422(19)30024-9","journal-title":"Lancet Neurol"},{"key":"5419_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41580-019-0185-4","volume":"21","author":"A Ballabio","year":"2020","unstructured":"Ballabio A, Bonifacino JS (2020) Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat Rev Mol Cell Biol 21:101\u2013118. https:\/\/doi.org\/10.1038\/s41580-019-0185-4","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5419_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-023-00676-x","author":"C Settembre","year":"2023","unstructured":"Settembre C, Perera RM (2023) Lysosomes as coordinators of cellular catabolism, metabolic signalling and organ physiology. Nat Rev Mol Cell Biol. https:\/\/doi.org\/10.1038\/s41580-023-00676-x","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5419_CR10","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1101\/gad.1599207","volume":"21","author":"N Mizushima","year":"2007","unstructured":"Mizushima N (2007) Autophagy: process and function. Genes Dev 21:2861\u20132873. https:\/\/doi.org\/10.1101\/gad.1599207","journal-title":"Genes Dev"},{"key":"5419_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/hmg\/ddm289","volume":"17","author":"C Settembre","year":"2008","unstructured":"Settembre C, Fraldi A, Jahreiss L et al (2008) A block of autophagy in lysosomal storage disorders. Hum Mol Genet 17:119\u2013129. https:\/\/doi.org\/10.1093\/hmg\/ddm289","journal-title":"Hum Mol Genet"},{"key":"5419_CR12","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.3390\/cells9112399","volume":"9","author":"A Navarro-Romero","year":"2020","unstructured":"Navarro-Romero A, Montpey\u00f3 M, Martinez-Vicente M (2020) The emerging role of the lysosome in Parkinson\u2019s disease. Cells 9:2399. https:\/\/doi.org\/10.3390\/cells9112399","journal-title":"Cells"},{"key":"5419_CR13","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1007\/s00415-023-11781-4","volume":"270","author":"J Yang","year":"2023","unstructured":"Yang J, Wu X, Song Y (2023) Recent advances in novel mutation genes of Parkinson\u2019s disease. J Neurol 270:3723\u20133732. https:\/\/doi.org\/10.1007\/s00415-023-11781-4","journal-title":"J Neurol"},{"key":"5419_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/mds.26477","volume":"31","author":"M Xilouri","year":"2016","unstructured":"Xilouri M, Brekk OR, Stefanis L (2016) Autophagy and alpha-synuclein: relevance to Parkinson\u2019s disease and related synucleopathies. Mov Disord 31:178\u2013192. https:\/\/doi.org\/10.1002\/mds.26477","journal-title":"Mov Disord"},{"key":"5419_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.nbd.2009.05.023","volume":"35","author":"Y Chu","year":"2009","unstructured":"Chu Y, Dodiya H, Aebischer P et al (2009) Alterations in lysosomal and proteasomal markers in Parkinson\u2019s disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 35:385\u2013398. https:\/\/doi.org\/10.1016\/j.nbd.2009.05.023","journal-title":"Neurobiol Dis"},{"key":"5419_CR16","doi-asserted-by":"publisher","first-page":"9611","DOI":"10.1073\/pnas.1112368109","volume":"109","author":"B Dehay","year":"2012","unstructured":"Dehay B, Ramirez A, Martinez-Vicente M et al (2012) Loss of P-type ATPase ATP13A2\/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci USA 109:9611\u20139616. https:\/\/doi.org\/10.1073\/pnas.1112368109","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"5419_CR17","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1007\/s12035-018-1090-0","volume":"56","author":"TE Moors","year":"2019","unstructured":"Moors TE, Paciotti S, Ingrassia A et al (2019) Characterization of brain lysosomal activities in GBA-related and sporadic Parkinson\u2019s disease and dementia with lewy bodies. Mol Neurobiol 56(2):1344\u20131355. https:\/\/doi.org\/10.1007\/s12035-018-1090-0","journal-title":"Mol Neurobiol"},{"issue":"1","key":"5419_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-017-0233-5","volume":"13","author":"SP Yun","year":"2018","unstructured":"Yun SP, Kim D, Kim S et al (2018) \u03b1-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Mol Neurodegener 13(1):1","journal-title":"Mol Neurodegener"},{"key":"5419_CR19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/WCO.0000000000000715","volume":"32","author":"E Ryan","year":"2019","unstructured":"Ryan E, Seehra G, Sharma P, Sidransky E (2019) GBA1-associated parkinsonism: new insights and therapeutic opportunities. Curr Opin Neurol 32:589\u2013596. https:\/\/doi.org\/10.1097\/WCO.0000000000000715","journal-title":"Curr Opin Neurol"},{"key":"5419_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.tins.2019.05.010","volume":"42","author":"T Farfel-Becker","year":"2019","unstructured":"Farfel-Becker T, Do J, Tayebi N, Sidransky E (2019) Can GBA1-associated Parkinson disease be modeled in the mouse? Trends Neurosci 42:631\u2013643. https:\/\/doi.org\/10.1016\/j.tins.2019.05.010","journal-title":"Trends Neurosci"},{"key":"5419_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104545","volume":"132","author":"LF Burbulla","year":"2019","unstructured":"Burbulla LF, Krainc D (2019) The role of dopamine in the pathogenesis of GBA1-linked Parkinson\u2019s disease. Neurobiol Dis 132:104545. https:\/\/doi.org\/10.1016\/j.nbd.2019.104545","journal-title":"Neurobiol Dis"},{"key":"5419_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11910-018-0860-4","volume":"18","author":"Z Gan-Or","year":"2018","unstructured":"Gan-Or Z, Liong C, Alcalay RN (2018) GBA-associated Parkinson\u2019s Disease and Other synucleinopathies. Curr Neurol Neurosci Rep 18:44. https:\/\/doi.org\/10.1007\/s11910-018-0860-4","journal-title":"Curr Neurol Neurosci Rep"},{"key":"5419_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-015-0010-2","author":"D Chiasserini","year":"2015","unstructured":"Chiasserini D, Paciotti S et al (2015) Selective loss of glucocerebrosidase activity in sporadic Parkinson\u2019s disease and dementia with Lewy bodies. Mol Neurodegener. https:\/\/doi.org\/10.1186\/s13024-015-0010-2","journal-title":"Mol Neurodegener"},{"key":"5419_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv179","author":"RN Alcalay","year":"2015","unstructured":"Alcalay RN, Levy OA, Waters CH et al (2015) Glucocerebrosidase activity in Parkinson\u2019s disease with and without GBA mutations. Brain. https:\/\/doi.org\/10.1093\/brain\/awv179","journal-title":"Brain"},{"key":"5419_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/mds.27583","volume":"34","author":"F Blandini","year":"2019","unstructured":"Blandini F, Cilia R, Cerri S et al (2019) Glucocerebrosidase mutations and synucleinopathies: toward a model of precision medicine. Mov Disord 34:9\u201321. https:\/\/doi.org\/10.1002\/mds.27583","journal-title":"Mov Disord"},{"key":"5419_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.nbd.2015.09.009","volume":"82","author":"EM Rocha","year":"2015","unstructured":"Rocha EM, Smith GA, Park E et al (2015) Glucocerebrosidase gene therapy prevents \u03b1-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis 82:495\u2013503. https:\/\/doi.org\/10.1016\/j.nbd.2015.09.009","journal-title":"Neurobiol Dis"},{"key":"5419_CR27","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.22400","volume":"69","author":"V Cullen","year":"2011","unstructured":"Cullen V, Sardi SP, Ng J et al (2011) Acid \u03b2-glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter \u03b1-synuclein processing. Ann Neurol 69:940\u2013953. https:\/\/doi.org\/10.1002\/ana.22400","journal-title":"Ann Neurol"},{"key":"5419_CR28","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/brain\/awt367","volume":"137","author":"KE Murphy","year":"2014","unstructured":"Murphy KE, Gysbers AM, Abbott SK et al (2014) Reduced glucocerebrosidase is associated with increased -synuclein in sporadic Parkinson\u2019s disease. Brain 137:834\u2013848. https:\/\/doi.org\/10.1093\/brain\/awt367","journal-title":"Brain"},{"key":"5419_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","volume":"16","author":"E Tolosa","year":"2020","unstructured":"Tolosa E, Vila M, Klein C, Rascol O (2020) LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol 16:97\u2013107. https:\/\/doi.org\/10.1038\/s41582-019-0301-2","journal-title":"Nat Rev Neurol"},{"key":"5419_CR30","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.31012","author":"S Martin","year":"2017","unstructured":"Martin S, Federico D, Dhekne HS et al (2017) Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. Elife. https:\/\/doi.org\/10.7554\/eLife.31012","journal-title":"Elife"},{"key":"5419_CR31","doi-asserted-by":"publisher","unstructured":"Schreij AM, Chaineau M, Ruan W, et al (2015) LRRK2 localizes to endosomes and interacts with clathrin-light chains to limit Rac1 activation. EMBO Reports 16:79\u201386. https:\/\/doi.org\/10.15252\/embr.201438714","DOI":"10.15252\/embr.201438714"},{"key":"5419_CR32","doi-asserted-by":"publisher","first-page":"eabb2454","DOI":"10.1126\/sciadv.abb2454","volume":"6","author":"L Bonet","year":"2020","unstructured":"Bonet L, Beilina A, Williamson CD et al (2020) LRRK2 mediates tubulation and vesicle sorting from lysosomes. Sci Adv 6:eabb2454. https:\/\/doi.org\/10.1126\/sciadv.abb2454","journal-title":"Sci Adv"},{"key":"5419_CR33","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3390\/biom13111645","volume":"13","author":"T Komori","year":"2023","unstructured":"Komori T, Kuwahara T (2023) An update on the interplay between LRRK2, Rab GTPases and Parkinson\u2019s disease. Biomolecules 13:1645. https:\/\/doi.org\/10.3390\/biom13111645","journal-title":"Biomolecules"},{"key":"5419_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40035-022-00281-6","volume":"11","author":"SY-Y Pang","year":"2022","unstructured":"Pang SY-Y, Lo RCN, Ho PW-L et al (2022) LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson\u2019s disease. Transl Neurodegener 11:5. https:\/\/doi.org\/10.1186\/s40035-022-00281-6","journal-title":"Transl Neurodegener"},{"key":"5419_CR35","doi-asserted-by":"publisher","first-page":"9879","DOI":"10.1073\/pnas.1004676107","volume":"107","author":"Y Tong","year":"2010","unstructured":"Tong Y, Yamaguchi H, Giaime E et al (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci USA 107:9879\u20139884. https:\/\/doi.org\/10.1073\/pnas.1004676107","journal-title":"Proc Natl Acad Sci USA"},{"key":"5419_CR36","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1093\/hmg\/ddr348","volume":"20","author":"MC Herzig","year":"2011","unstructured":"Herzig MC, Kolly C, Persohn E et al (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 20:4209\u20134223. https:\/\/doi.org\/10.1093\/hmg\/ddr348","journal-title":"Hum Mol Genet"},{"key":"5419_CR37","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1093\/hmg\/ddu138","volume":"23","author":"J Schapansky","year":"2014","unstructured":"Schapansky J, Nardozzi JD, Felizia F, LaVoie MJ (2014) Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. Hum Mol Genet 23:4201\u20134214. https:\/\/doi.org\/10.1093\/hmg\/ddu138","journal-title":"Hum Mol Genet"},{"key":"5419_CR38","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.bbamcr.2013.07.020","volume":"1833","author":"C Manzoni","year":"2013","unstructured":"Manzoni C, Mamais A, Dihanich S et al (2013) Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim Biophys Acta 1833:2900\u20132910. https:\/\/doi.org\/10.1016\/j.bbamcr.2013.07.020","journal-title":"Biochim Biophys Acta"},{"key":"5419_CR39","doi-asserted-by":"publisher","first-page":"35106","DOI":"10.1038\/srep35106","volume":"6","author":"C Manzoni","year":"2016","unstructured":"Manzoni C, Mamais A, Roosen DA et al (2016) mTOR independent regulation of macroautophagy by leucine Rich Repeat kinase 2 via beclin-1. Sci Rep 6:35106. https:\/\/doi.org\/10.1038\/srep35106","journal-title":"Sci Rep"},{"key":"5419_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1750-1326-7-2","volume":"7","author":"Y Tong","year":"2012","unstructured":"Tong Y, Giaime E, Yamaguchi H et al (2012) Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener 7:2. https:\/\/doi.org\/10.1186\/1750-1326-7-2","journal-title":"Mol Neurodegener"},{"key":"5419_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104626","volume":"134","author":"EM Rocha","year":"2019","unstructured":"Rocha EM, Miranda B, Castro S et al (2019) LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson\u2019s disease. Neurobiol Dis 134:104626. https:\/\/doi.org\/10.1016\/j.nbd.2019.104626","journal-title":"Neurobiol Dis"},{"key":"5419_CR42","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/jb\/mvv005","volume":"157","author":"YH Jin","year":"2015","unstructured":"Jin YH, Hyejung K, Inhwa G et al (2015) An early endosome regulator, Rab5b, is an LRRK2 kinase substrate. J Biochem 157:485\u2013495. https:\/\/doi.org\/10.1093\/jb\/mvv005","journal-title":"J Biochem"},{"key":"5419_CR43","doi-asserted-by":"publisher","first-page":"E9115","DOI":"10.1073\/pnas.1812196115","volume":"115","author":"T Eguchi","year":"2018","unstructured":"Eguchi T, Kuwahara T, Sakurai M et al (2018) LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis. Proc Natl Acad Sci USA 115:E9115\u2013E9124. https:\/\/doi.org\/10.1073\/pnas.1812196115","journal-title":"Proc Natl Acad Sci USA"},{"key":"5419_CR44","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1093\/hmg\/ddz136","volume":"28","author":"S Jinn","year":"2019","unstructured":"Jinn S, Blauwendraat C, Toolan D et al (2019) Functionalization of the TMEM175 p. M393T variant as a risk factor for Parkinson disease. Hum Mol Genet 28:3244\u20133254. https:\/\/doi.org\/10.1093\/hmg\/ddz136","journal-title":"Hum Mol Genet"},{"key":"5419_CR45","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00401-012-1013-5","volume":"124","author":"H Houlden","year":"2012","unstructured":"Houlden H, Singleton AB (2012) The genetics and neuropathology of Parkinson\u2019s disease. Acta Neuropathol 124:325\u2013338. https:\/\/doi.org\/10.1007\/s00401-012-1013-5","journal-title":"Acta Neuropathol"},{"key":"5419_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ana.25629","volume":"87","author":"L Krohn","year":"2020","unstructured":"Krohn L, \u00d6zt\u00fcrk TN, Vanderperre B et al (2020) Genetic, structural, and functional evidence link TMEM175 to synucleinopathies. Ann Neurol 87:139\u2013153. https:\/\/doi.org\/10.1002\/ana.25629","journal-title":"Ann Neurol"},{"key":"5419_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106244","volume":"185","author":"L Wu","year":"2023","unstructured":"Wu L, Lin Y, Song J et al (2023) TMEM175: a lysosomal ion channel associated with neurological diseases. Neurobiol Dis 185:106244. https:\/\/doi.org\/10.1016\/j.nbd.2023.106244","journal-title":"Neurobiol Dis"},{"key":"5419_CR48","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.cell.2015.08.002","volume":"162","author":"C Cang","year":"2015","unstructured":"Cang C, Aranda K, Seo Y et al (2015) TMEM175 is an organelle K (+) channel regulating lysosomal function. Cell 162:1101\u20131112. https:\/\/doi.org\/10.1016\/j.cell.2015.08.002","journal-title":"Cell"},{"key":"5419_CR49","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1073\/pnas.1616332114","volume":"114","author":"S Jinn","year":"2017","unstructured":"Jinn S, Drolet RE, Cramer PE et al (2017) TMEM175 deficiency impairs lysosomal and mitochondrial function and increases \u03b1-synuclein aggregation. Proc Natl Acad Sci USA 114:2389\u20132394. https:\/\/doi.org\/10.1073\/pnas.1616332114","journal-title":"Proc Natl Acad Sci USA"},{"key":"5419_CR50","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/biom13050802","volume":"13","author":"T Tang","year":"2023","unstructured":"Tang T, Jian B, Liu Z (2023) Transmembrane protein 175, a lysosomal ion channel related to Parkinson\u2019s disease. Biomolecules 13:802. https:\/\/doi.org\/10.3390\/biom13050802","journal-title":"Biomolecules"},{"key":"5419_CR51","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/mds.26243","volume":"30","author":"J-S Park","year":"2015","unstructured":"Park J-S, Blair NF, Sue CM (2015) The role of ATP13A2 in Parkinson\u2019s disease: clinical phenotypes and molecular mechanisms. Mov Disord 30:770\u2013779. https:\/\/doi.org\/10.1002\/mds.26243","journal-title":"Mov Disord"},{"key":"5419_CR52","doi-asserted-by":"publisher","first-page":"11803","DOI":"10.1038\/ncomms11803","volume":"7","author":"CF Bento","year":"2016","unstructured":"Bento CF, Ashkenazi A, Jimenez-Sanchez M, Rubinsztein DC (2016) The Parkinson\u2019s disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway. Nat Commun 7:11803. https:\/\/doi.org\/10.1038\/ncomms11803","journal-title":"Nat Commun"},{"key":"5419_CR53","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1016\/j.molcel.2021.10.002","volume":"81","author":"J Tillinghast","year":"2021","unstructured":"Tillinghast J, Drury S, Bowser D et al (2021) Structural mechanisms for gating and ion selectivity of the human polyamine transporter ATP13A2. Mol Cell 81:4650-4662.e4. https:\/\/doi.org\/10.1016\/j.molcel.2021.10.002","journal-title":"Mol Cell"},{"key":"5419_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.927682","volume":"16","author":"F Zhang","year":"2022","unstructured":"Zhang F, Wu Z, Long F et al (2022) The Roles of ATP13A2 gene mutations leading to abnormal aggregation of \u03b1-synuclein in Parkinson\u2019s disease. Front Cell Neurosci 16:927682. https:\/\/doi.org\/10.3389\/fncel.2022.927682","journal-title":"Front Cell Neurosci"},{"key":"5419_CR55","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.4161\/auto.21011","volume":"8","author":"B Dehay","year":"2012","unstructured":"Dehay B, Martinez-Vicente M, Ramirez A et al (2012) Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove. Autophagy 8:1389\u20131391. https:\/\/doi.org\/10.4161\/auto.21011","journal-title":"Autophagy"},{"key":"5419_CR56","doi-asserted-by":"publisher","first-page":"eaan2788","DOI":"10.1126\/science.aan2788","volume":"359","author":"F Madeo","year":"2018","unstructured":"Madeo F, Eisenberg T, Pietrocola F, Kroemer G (2018) Spermidine in health and disease. Science 359:eaan2788","journal-title":"Science"},{"key":"5419_CR57","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/ng1884","volume":"38","author":"A Ramirez","year":"2006","unstructured":"Ramirez A, Heimbach A, Gr\u00fcndemann J et al (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38:1184\u20131191. https:\/\/doi.org\/10.1038\/ng1884","journal-title":"Nat Genet"},{"key":"5419_CR58","doi-asserted-by":"publisher","first-page":"31198","DOI":"10.1073\/pnas.1922342117","volume":"117","author":"S Vrijsen","year":"2020","unstructured":"Vrijsen S, Besora-Casals L, van Veen S et al (2020) ATP13A2-mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress. Proc Natl Acad Sci USA 117:31198\u201331207. https:\/\/doi.org\/10.1073\/pnas.1922342117","journal-title":"Proc Natl Acad Sci USA"},{"key":"5419_CR59","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41586-020-1968-7","volume":"578","author":"S van Veen","year":"2020","unstructured":"van Veen S, Martin S, Van den Haute C et al (2020) ATP13A2 deficiency disrupts lysosomal polyamine export. Nature 578:419\u2013424. https:\/\/doi.org\/10.1038\/s41586-020-1968-7","journal-title":"Nature"},{"key":"5419_CR60","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2051-5960-1-11","volume":"1","author":"KE Murphy","year":"2013","unstructured":"Murphy KE, Cottle L, Gysbers AM et al (2013) ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol Commun 1:11. https:\/\/doi.org\/10.1186\/2051-5960-1-11","journal-title":"Acta Neuropathol Commun"},{"key":"5419_CR61","doi-asserted-by":"publisher","first-page":"9040","DOI":"10.1073\/pnas.1508220112","volume":"112","author":"T Holemans","year":"2015","unstructured":"Holemans T, S\u00f8rensen DM, van Veen S et al (2015) A lipid switch unlocks Parkinson\u2019s disease-associated ATP13A2. Proc Natl Acad Sci USA 112:9040\u20139045. https:\/\/doi.org\/10.1073\/pnas.1508220112","journal-title":"Proc Natl Acad Sci USA"},{"key":"5419_CR62","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/mds.25430","volume":"28","author":"H Deng","year":"2013","unstructured":"Deng H, Gao K, Jankovic J (2013) The VPS35 gene and Parkinson\u2019s disease. Mov Disord 28:569\u2013575. https:\/\/doi.org\/10.1002\/mds.25430","journal-title":"Mov Disord"},{"key":"5419_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105056","volume":"145","author":"G Cutillo","year":"2020","unstructured":"Cutillo G, Simon DK, Eleuteri S (2020) VPS35 and the mitochondria: connecting the dots in Parkinson\u2019s disease pathophysiology. Neurobiol Dis 145:105056. https:\/\/doi.org\/10.1016\/j.nbd.2020.105056","journal-title":"Neurobiol Dis"},{"key":"5419_CR64","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3389\/fneur.2019.01272","volume":"10","author":"S Eleuteri","year":"2019","unstructured":"Eleuteri S, Albanese A (2019) VPS35-based approach: a potential innovative treatment in Parkinson\u2019s disease. Front Neurol 10:1272. https:\/\/doi.org\/10.3389\/fneur.2019.01272","journal-title":"Front Neurol"},{"key":"5419_CR65","doi-asserted-by":"publisher","first-page":"10613","DOI":"10.1523\/JNEUROSCI.0042-15.2015","volume":"35","author":"FL Tang","year":"2015","unstructured":"Tang FL, Erion JR, Yun T et al (2015) VPS35 in dopamine neurons is required for endosome-to-golgi retrieval of Lamp2a, a receptor of chaperone-mediated autophagy that is critical for \u03b1-synuclein degradation and prevention of pathogenesis of Parkinson\u2019s disease. J Neurosci 35:10613\u201310628. https:\/\/doi.org\/10.1523\/JNEUROSCI.0042-15.2015","journal-title":"J Neurosci"},{"key":"5419_CR66","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1038\/ncomms4828","volume":"5","author":"E Zavodszky","year":"2014","unstructured":"Zavodszky E, Seaman MNJ, Moreau K et al (2014) Mutation in VPS35 associated with Parkinson\u2019s disease impairs WASH complex association and inhibits autophagy. Nat Commun 5:3828. https:\/\/doi.org\/10.1038\/ncomms4828","journal-title":"Nat Commun"},{"key":"5419_CR67","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1083\/jcb.201105109","volume":"195","author":"L Wen","year":"2011","unstructured":"Wen L, Tang F-L, Hong Y et al (2011) VPS35 haploinsufficiency increases Alzheimer\u2019s disease neuropathology. J Cell Biol 195:765\u2013779. https:\/\/doi.org\/10.1083\/jcb.201105109","journal-title":"J Cell Biol"},{"key":"5419_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2014.07.014","volume":"71","author":"E Miura","year":"2014","unstructured":"Miura E, Hasegawa T, Konno M et al (2014) VPS35 dysfunction impairs lysosomal degradation of \u03b1-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson\u2019s disease. Neurobiol Dis 71:1\u201313. https:\/\/doi.org\/10.1016\/j.nbd.2014.07.014","journal-title":"Neurobiol Dis"},{"key":"5419_CR69","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.cub.2010.05.066","volume":"20","author":"E Braschi","year":"2010","unstructured":"Braschi E, Goyon V, Zunino R et al (2010) Vps35 mediates vesicle transport between the mitochondria and peroxisomes. Curr Biol 20:1310\u20131315. https:\/\/doi.org\/10.1016\/j.cub.2010.05.066","journal-title":"Curr Biol"},{"key":"5419_CR70","doi-asserted-by":"publisher","first-page":"18578","DOI":"10.1073\/pnas.0804373105","volume":"105","author":"J Salazar","year":"2008","unstructured":"Salazar J, Mena N, Hunot S et al (2008) Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson\u2019s disease. Proc Natl Acad Sci USA 105:18578\u201318583. https:\/\/doi.org\/10.1073\/pnas.0804373105","journal-title":"Proc Natl Acad Sci USA"},{"key":"5419_CR71","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1212\/wnl.0b013e3181a26b30","volume":"72","author":"EE Benarroch","year":"2009","unstructured":"Benarroch EE (2009) Brain iron homeostasis and neurodegenerative disease. Neurology 72:1436\u20131440. https:\/\/doi.org\/10.1212\/wnl.0b013e3181a26b30","journal-title":"Neurology"},{"issue":"9","key":"5419_CR72","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.cellbi.2008.01.057","volume":"30","author":"SZ Zhang","year":"2009","unstructured":"Zhang SZ, Wang J, Song N et al (2009) (2008) Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP+) -induced apoptosis in MES23.5 cells. Neurobiol Aging. 30(9):1466\u20131476. https:\/\/doi.org\/10.1016\/j.cellbi.2008.01.057","journal-title":"Neurobiol Aging."},{"key":"5419_CR73","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1242\/jcs.060574","volume":"123","author":"M Tabuchi","year":"2010","unstructured":"Tabuchi M, Yanatori I, Kawai Y, Kishi F (2010) Retromer-mediated direct sorting is required for proper endosomal recycling of the mammalian iron transporter DMT1. J Cell Sci 123:756\u2013766. https:\/\/doi.org\/10.1242\/jcs.060574","journal-title":"J Cell Sci"},{"key":"5419_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2022.119243","volume":"1869","author":"A Drobny","year":"2022","unstructured":"Drobny A, Prieto Huarcaya S, Dobert J et al (2022) The role of lysosomal cathepsins in neurodegeneration: Mechanistic insights, diagnostic potential and therapeutic approaches. Biochim Biophys Acta Mol Cell Res 1869:119243. https:\/\/doi.org\/10.1016\/j.bbamcr.2022.119243","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"5419_CR75","doi-asserted-by":"publisher","first-page":"9322","DOI":"10.1073\/pnas.1500937112","volume":"112","author":"RO McGlinchey","year":"2015","unstructured":"McGlinchey RO, Lee JC (2015) Cysteine cathepsins are essential in lysosomal degradation of \u03b1-synuclein. Proc Natl Acad Sci USA 112:9322\u20139327. https:\/\/doi.org\/10.1073\/pnas.1500937112","journal-title":"Proc Natl Acad Sci USA"},{"key":"5419_CR76","doi-asserted-by":"publisher","first-page":"9678","DOI":"10.1021\/bi800699v","volume":"47","author":"D Sevlever","year":"2008","unstructured":"Sevlever D, Jiang P, Yen S-HC (2008) Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 47:9678\u20139687. https:\/\/doi.org\/10.1021\/bi800699v","journal-title":"Biochemistry"},{"key":"5419_CR77","doi-asserted-by":"publisher","unstructured":"Liu F, Li X, Lu C, et al (2016) Ceramide activates lysosomal cathepsin B and cathepsin D to attenuate autophagy and induces ER stress to suppress myeloid-derived suppressor cells. Oncotarget 7:83907\u201383925. https:\/\/doi.org\/10.18632\/oncotarget.13438","DOI":"10.18632\/oncotarget.13438"},{"key":"5419_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.128","volume":"47","author":"E-J Bae","year":"2015","unstructured":"Bae E-J, Yang NY, Lee C et al (2015) Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and \u03b1-synuclein aggregation. Exp Mol Med 47:e153. https:\/\/doi.org\/10.1038\/emm.2014.128","journal-title":"Exp Mol Med"},{"key":"5419_CR79","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv372","author":"M Suzuki","year":"2015","unstructured":"Suzuki M, Fujikake N et al (2015) Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant \u03b1-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson\u2019s disease. Hum Mol Genet. https:\/\/doi.org\/10.1093\/hmg\/ddv372","journal-title":"Hum Mol Genet"},{"key":"5419_CR80","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"J Mazzulli","year":"2011","unstructured":"Mazzulli J, Xu YH, Ying S et al (2011) Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146:37\u201352. https:\/\/doi.org\/10.1016\/j.cell.2011.06.001","journal-title":"Cell"},{"key":"5419_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2015.12.013","volume":"613","author":"M Moraitou","year":"2016","unstructured":"Moraitou M, Dermentzaki G, Dimitriou E et al (2016) \u03b1-Synuclein dimerization in erythrocytes of Gaucher disease patients: correlation with lipid abnormalities and oxidative stress. Neurosci Lett 613:1\u20135. https:\/\/doi.org\/10.1016\/j.neulet.2015.12.013","journal-title":"Neurosci Lett"},{"key":"5419_CR82","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.neuron.2017.12.012","volume":"97","author":"F Zunke","year":"2018","unstructured":"Zunke F, Moise AC, Belur NR et al (2018) Reversible conformational conversion of \u03b1-synuclein into toxic assemblies by glucosylceramide. Neuron 97:92-107.e10. https:\/\/doi.org\/10.1016\/j.neuron.2017.12.012","journal-title":"Neuron"},{"key":"5419_CR83","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1523\/JNEUROSCI.0680-22.2022","volume":"43","author":"CL Mahoney-Crane","year":"2023","unstructured":"Mahoney-Crane CL, Viswanathan M, Russell D et al (2023) Neuronopathic GBA1L444P mutation accelerates glucosylsphingosine levels and formation of hippocampal alpha-synuclein inclusions. J Neurosci 43:501\u2013521. https:\/\/doi.org\/10.1523\/JNEUROSCI.0680-22.2022","journal-title":"J Neurosci"},{"key":"5419_CR84","doi-asserted-by":"publisher","first-page":"5252","DOI":"10.1093\/emboj\/18.19.5252","volume":"18","author":"M Heinrich","year":"1999","unstructured":"Heinrich M, Wickel M, Schneider-Brachert W et al (1999) Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J 18:5252\u20135263. https:\/\/doi.org\/10.1093\/emboj\/18.19.5252","journal-title":"EMBO J"},{"key":"5419_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073094","volume":"8","author":"MM Mielke","year":"2013","unstructured":"Mielke MM, Maetzler W, Haughey NJ et al (2013) Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson\u2019s disease and associated with cognitive impairment: a pilot study. PLoS One 8:e73094. https:\/\/doi.org\/10.1371\/journal.pone.0073094","journal-title":"PLoS One"},{"key":"5419_CR86","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.molmed.2018.10.009","volume":"25","author":"J Kurz","year":"2019","unstructured":"Kurz J, Parnham MJ, Geisslinger G, Schiffmann S (2019) Ceramides as novel disease biomarkers. Trends Mol Med 25:20\u201332. https:\/\/doi.org\/10.1016\/j.molmed.2018.10.009","journal-title":"Trends Mol Med"},{"key":"5419_CR87","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/mds.25729","volume":"29","author":"SK Abbott","year":"2014","unstructured":"Abbott SK, Li H, Mu\u00f1oz SS et al (2014) Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson\u2019s disease. Mov Disord 29:518\u2013526. https:\/\/doi.org\/10.1002\/mds.25729","journal-title":"Mov Disord"},{"key":"5419_CR88","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1093\/hmg\/ddy105","volume":"27","author":"MJ Kim","year":"2018","unstructured":"Kim MJ, Jeon S, Burbulla LF, Krainc D (2018) Acid ceramidase inhibition ameliorates \u03b1-synuclein accumulation upon loss of GBA1 function. Hum Mol Genet 27:1972\u20131988. https:\/\/doi.org\/10.1093\/hmg\/ddy105","journal-title":"Hum Mol Genet"},{"key":"5419_CR89","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/brain\/awab371","volume":"145","author":"C Galvagnion","year":"2022","unstructured":"Galvagnion C, Marlet FR, Cerri S et al (2022) Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote \u03b1-synuclein aggregation. Brain 145:1038\u20131051. https:\/\/doi.org\/10.1093\/brain\/awab371","journal-title":"Brain"},{"key":"5419_CR90","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/ng.3955","volume":"49","author":"D Chang","year":"2017","unstructured":"Chang D, Nalls MA, Hallgr\u00edmsd\u00f3ttir IB et al (2017) A meta-analysis of genome-wide association studies identifies 17 new Parkinson\u2019s disease risk loci. Nat Genet 49:1511\u20131516. https:\/\/doi.org\/10.1038\/ng.3955","journal-title":"Nat Genet"},{"key":"5419_CR91","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1212\/WNL.0b013e31828f180e","volume":"80","author":"Z Gan-Or","year":"2013","unstructured":"Gan-Or Z, Ozelius LJ, Bar-Shira A et al (2013) The p. L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 80:1606\u20131610. https:\/\/doi.org\/10.1212\/WNL.0b013e31828f180e","journal-title":"Neurology"},{"key":"5419_CR92","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.parkreldis.2015.06.016","volume":"21","author":"E Dagan","year":"2015","unstructured":"Dagan E, Schlesinger I, Ayoub M et al (2015) The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. Parkinsonism Relat Disord 21:1067\u20131071. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.06.016","journal-title":"Parkinsonism Relat Disord"},{"key":"5419_CR93","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/mds.27642","volume":"34","author":"RN Alcalay","year":"2019","unstructured":"Alcalay RN, Mallett V, Vanderperre B et al (2019) SMPD1 mutations, activity, and \u03b1-synuclein accumulation in Parkinson\u2019s disease. Mov Disord 34:526\u2013535. https:\/\/doi.org\/10.1002\/mds.27642","journal-title":"Mov Disord"},{"key":"5419_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193438","volume":"13","author":"MS Marshall","year":"2018","unstructured":"Marshall MS, Jakubauskas B, Bogue W et al (2018) Analysis of age-related changes in psychosine metabolism in the human brain. PLoS One 13:e0193438. https:\/\/doi.org\/10.1371\/journal.pone.0193438","journal-title":"PLoS One"},{"key":"5419_CR95","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/path.4328","volume":"232","author":"BR Smith","year":"2014","unstructured":"Smith BR, Santos MB, Marshall MS et al (2014) Neuronal inclusions of \u03b1-synuclein contribute to the pathogenesis of Krabbe disease. J Pathol 232:509\u2013521. https:\/\/doi.org\/10.1002\/path.4328","journal-title":"J Pathol"},{"key":"5419_CR96","doi-asserted-by":"publisher","first-page":"25009","DOI":"10.1074\/jbc.M300227200","volume":"278","author":"JL Webb","year":"2003","unstructured":"Webb JL, Ravikumar B, Atkins J et al (2003) \u03b1-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278:25009\u201325013. https:\/\/doi.org\/10.1074\/jbc.M300227200","journal-title":"J Biol Chem"},{"key":"5419_CR97","doi-asserted-by":"publisher","first-page":"754","DOI":"10.4161\/auto.19371","volume":"8","author":"J Klucken","year":"2012","unstructured":"Klucken J, Poehler A-M, Ebrahimi-Fakhari D et al (2012) Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy 8:754\u2013766. https:\/\/doi.org\/10.4161\/auto.19371","journal-title":"Autophagy"},{"key":"5419_CR98","doi-asserted-by":"publisher","first-page":"23542","DOI":"10.1074\/jbc.M801992200","volume":"283","author":"T Vogiatzi","year":"2008","unstructured":"Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L (2008) Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem 283:23542\u201323556. https:\/\/doi.org\/10.1074\/jbc.M801992200","journal-title":"J Biol Chem"},{"key":"5419_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pbb.2018.12.005","volume":"177","author":"AB Pupyshev","year":"2019","unstructured":"Pupyshev AB, Tikhonova MA, Akopyan AA et al (2019) Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson\u2019s disease. Pharmacol Biochem Behav 177:1\u201311. https:\/\/doi.org\/10.1016\/j.pbb.2018.12.005","journal-title":"Pharmacol Biochem Behav"},{"key":"5419_CR100","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.tcb.2012.05.006","volume":"22","author":"S Kaushik","year":"2012","unstructured":"Kaushik S, Cuervo AM (2012) Chaperone-mediated autophagy: a unique way to enter the lysosome world. Trends Cell Biol 22:407\u2013417. https:\/\/doi.org\/10.1016\/j.tcb.2012.05.006","journal-title":"Trends Cell Biol"},{"key":"5419_CR101","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1126\/science.1101738","volume":"305","author":"AM Cuervo","year":"2004","unstructured":"Cuervo AM, Stefanis L, Fredenburg R et al (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305:1292\u20131295. https:\/\/doi.org\/10.1126\/science.1101738","journal-title":"Science"},{"key":"5419_CR102","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/mds.26141","volume":"30","author":"KE Murphy","year":"2015","unstructured":"Murphy KE, Gysbers AM, Abbott SK et al (2015) Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson\u2019s disease. Mov Disord 30:1639\u20131647. https:\/\/doi.org\/10.1002\/mds.26141","journal-title":"Mov Disord"},{"key":"5419_CR103","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1007\/s10495-010-0475-y","volume":"15","author":"Q Yang","year":"2010","unstructured":"Yang Q, Mao Z (2010) Dysregulation of autophagy and Parkinson\u2019s disease: the MEF2D link. Apoptosis 15:1410\u20131414. https:\/\/doi.org\/10.1007\/s10495-010-0475-y","journal-title":"Apoptosis"},{"key":"5419_CR104","doi-asserted-by":"publisher","first-page":"429","DOI":"10.4161\/auto.7.4.14393","volume":"7","author":"AR Winslow","year":"2011","unstructured":"Winslow AR, Rubinsztein DC (2011) The Parkinson disease protein \u03b1-synuclein inhibits autophagy. Autophagy 7:429\u2013431. https:\/\/doi.org\/10.4161\/auto.7.4.14393","journal-title":"Autophagy"},{"key":"5419_CR105","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.nbd.2010.07.006","volume":"43","author":"H Koga","year":"2011","unstructured":"Koga H, Cuervo AM (2011) Chaperone-mediated autophagy dysfunction in the pathogenesis of neurodegeneration. Neurobiol Dis 43:29\u201337. https:\/\/doi.org\/10.1016\/j.nbd.2010.07.006","journal-title":"Neurobiol Dis"},{"key":"5419_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/S41531-019-0103-7","author":"S Fanning","year":"2020","unstructured":"Fanning S, Selkoe D, Dettmer U (2020) Parkinson\u2019s disease: proteinopathy or lipidopathy? Nat Publ Group. https:\/\/doi.org\/10.1038\/S41531-019-0103-7","journal-title":"Nat Publ Group"},{"key":"5419_CR107","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12974-019-1532-2","volume":"16","author":"PJ Hallett","year":"2019","unstructured":"Hallett PJ, Engelender S, Isacson O (2019) Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson\u2019s disease. J Neuroinflammation 16:153. https:\/\/doi.org\/10.1186\/s12974-019-1532-2","journal-title":"J Neuroinflammation"},{"key":"5419_CR108","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.parkreldis.2017.08.026","volume":"44","author":"LC Guedes","year":"2017","unstructured":"Guedes LC, Chan RB, Gomes MA et al (2017) Serum lipid alterations in GBA-associated Parkinson\u2019s disease. Parkinsonism Relat Disord 44:58\u201365. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.08.026","journal-title":"Parkinsonism Relat Disord"},{"key":"5419_CR109","doi-asserted-by":"publisher","first-page":"E27","DOI":"10.3390\/cells8010027","volume":"8","author":"H Xicoy","year":"2019","unstructured":"Xicoy H, Wieringa B, Martens GJM (2019) The role of lipids in Parkinson\u2019s disease. Cells 8:E27. https:\/\/doi.org\/10.3390\/cells8010027","journal-title":"Cells"},{"key":"5419_CR110","doi-asserted-by":"publisher","unstructured":"Shin DW (2020) Lipophagy: Molecular Mechanisms and Implications in Metabolic Disorders. Mol Cells 43:686\u2013693. https:\/\/doi.org\/10.14348\/molcells.2020.0046","DOI":"10.14348\/molcells.2020.0046"},{"key":"5419_CR111","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","volume":"22","author":"SH Shahmoradian","year":"2019","unstructured":"Shahmoradian SH, Lewis AJ, Genoud C et al (2019) Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes. Nat Neurosci 22:1099\u20131109. https:\/\/doi.org\/10.1038\/s41593-019-0423-2","journal-title":"Nat Neurosci"},{"key":"5419_CR112","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00401-007-0264-z","volume":"114","author":"K Suzuki","year":"2007","unstructured":"Suzuki K, Iseki E, Togo T et al (2007) Neuronal and glial accumulation of alpha- and beta-synucleins in human lipidoses. Acta Neuropathol 114:481\u2013489. https:\/\/doi.org\/10.1007\/s00401-007-0264-z","journal-title":"Acta Neuropathol"},{"key":"5419_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106553","volume":"198","author":"A Ali","year":"2024","unstructured":"Ali A, Holman AP, Rodriguez A et al (2024) Elucidating the mechanisms of \u03b1-Synuclein-lipid interactions using site-directed mutagenesis. Neurobiol Dis 198:106553. https:\/\/doi.org\/10.1016\/j.nbd.2024.106553","journal-title":"Neurobiol Dis"},{"key":"5419_CR114","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.nbd.2018.01.012","volume":"112","author":"RN Alcalay","year":"2018","unstructured":"Alcalay RN, Wolf P, Levy OA et al (2018) Alpha galactosidase A activity in Parkinson\u2019s disease. Neurobiol Dis 112:85\u201390. https:\/\/doi.org\/10.1016\/j.nbd.2018.01.012","journal-title":"Neurobiol Dis"},{"key":"5419_CR115","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.nbd.2017.11.006","volume":"110","author":"MP Nelson","year":"2018","unstructured":"Nelson MP, Boutin M, Tse TE et al (2018) The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson\u2019s disease brain in association with the pathologic accumulation of alpha-synuclein. Neurobiol Dis 110:68\u201381. https:\/\/doi.org\/10.1016\/j.nbd.2017.11.006","journal-title":"Neurobiol Dis"},{"key":"5419_CR116","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jns.2008.04.011","volume":"271","author":"G Wu","year":"2008","unstructured":"Wu G, Yan B, Wang X et al (2008) Decreased activities of lysosomal acid alpha-D-galactosidase A in the leukocytes of sporadic Parkinson\u2019s disease. J Neurol Sci 271:168\u2013173. https:\/\/doi.org\/10.1016\/j.jns.2008.04.011","journal-title":"J Neurol Sci"},{"key":"5419_CR117","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.nbd.2009.03.002","volume":"34","author":"L Parnetti","year":"2009","unstructured":"Parnetti L, Balducci C, Pierguidi L et al (2009) Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. Neurobiol Dis 34:484\u2013486. https:\/\/doi.org\/10.1016\/j.nbd.2009.03.002","journal-title":"Neurobiol Dis"},{"key":"5419_CR118","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/mds.27136","volume":"32","author":"L Parnetti","year":"2017","unstructured":"Parnetti L, Paciotti S, Eusebi P et al (2017) Cerebrospinal fluid \u03b2-glucocerebrosidase activity is reduced in Parkinson\u2019s disease patients. Mov Disord 32:1423\u20131431. https:\/\/doi.org\/10.1002\/mds.27136","journal-title":"Mov Disord"},{"key":"5419_CR119","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1073\/pnas.1220464110","volume":"110","author":"SP Sardi","year":"2013","unstructured":"Sardi SP, Clarke J, Viel C et al (2013) Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci USA 110:3537\u20133542. https:\/\/doi.org\/10.1073\/pnas.1220464110","journal-title":"Proc Natl Acad Sci USA"},{"key":"5419_CR120","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fnins.2018.00081","volume":"12","author":"K Abul","year":"2018","unstructured":"Abul K, Dhanushkodi NR, Ardah MT et al (2018) Silencing of glucocerebrosidase gene in Drosophila enhances the aggregation of Parkinson\u2019s disease associated \u03b1-synuclein mutant A53T and affects locomotor activity. Front Neurosci 12:81. https:\/\/doi.org\/10.3389\/fnins.2018.00081","journal-title":"Front Neurosci"},{"key":"5419_CR121","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/med.21394","volume":"36","author":"C Vidoni","year":"2016","unstructured":"Vidoni C, Follo C, Savino M et al (2016) The role of cathepsin D in the pathogenesis of human neurodegenerative disorders. Med Res Rev 36:845\u2013870. https:\/\/doi.org\/10.1002\/med.21394","journal-title":"Med Res Rev"},{"key":"5419_CR122","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/mds.26141","volume":"30","author":"KE Murphy","year":"2015","unstructured":"Murphy KE, Gysbers AM, Abbott SK et al (2015) Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 30:1639\u20131647. https:\/\/doi.org\/10.1002\/mds.26141","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"5419_CR123","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/s41598-018-19479-8","volume":"8","author":"J Magalhaes","year":"2018","unstructured":"Magalhaes J, Gegg ME, Migdalska-Richards A, Schapira AH (2018) Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. Sci Rep 8:1385. https:\/\/doi.org\/10.1038\/s41598-018-19479-8","journal-title":"Sci Rep"},{"key":"5419_CR124","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.nbd.2015.06.008","volume":"82","author":"G Ambrosi","year":"2015","unstructured":"Ambrosi G, Ghezzi C, Zangaglia R et al (2015) Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson\u2019s disease cells. Neurobiol Dis 82:235\u2013242. https:\/\/doi.org\/10.1016\/j.nbd.2015.06.008","journal-title":"Neurobiol Dis"},{"key":"5419_CR125","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ana.24790","volume":"80","author":"A Migdalska-Richards","year":"2016","unstructured":"Migdalska-Richards A, Daly L, Bezard E, Schapira AHV (2016) Ambroxol effects in glucocerebrosidase and \u03b1-synuclein transgenic mice. Ann Neurol 80:766\u2013775. https:\/\/doi.org\/10.1002\/ana.24790","journal-title":"Ann Neurol"},{"key":"5419_CR126","doi-asserted-by":"publisher","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","volume":"36","author":"E Aflaki","year":"2016","unstructured":"Aflaki E, Borger DK, Moaven N et al (2016) A new glucocerebrosidase chaperone reduces \u03b1-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism. J Neurosci 36:7441\u20137452. https:\/\/doi.org\/10.1523\/JNEUROSCI.0636-16.2016","journal-title":"J Neurosci"},{"key":"5419_CR127","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","volume":"137","author":"A McNeill","year":"2014","unstructured":"McNeill A, Magalhaes J, Shen C et al (2014) Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137:1481\u20131495. https:\/\/doi.org\/10.1093\/brain\/awu020","journal-title":"Brain"},{"key":"5419_CR128","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin S, Smith L, Lee K et al (2020) Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations. JAMA Neurol 77:427\u2013434. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4611","journal-title":"JAMA Neurol"},{"key":"5419_CR129","doi-asserted-by":"publisher","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","volume":"36","author":"JR Mazzulli","year":"2016","unstructured":"Mazzulli JR, Zunke F, Tsunemi T et al (2016) Activation of \u03b2-Glucocerebrosidase reduces pathological \u03b1-synuclein and restores lysosomal function in Parkinson\u2019s patient midbrain neurons. J Neurosci 36:7693\u20137706. https:\/\/doi.org\/10.1523\/JNEUROSCI.0628-16.2016","journal-title":"J Neurosci"},{"key":"5419_CR130","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1073\/pnas.1616152114","volume":"114","author":"SP Sardi","year":"2017","unstructured":"Sardi SP, Viel C, Clarke J et al (2017) Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proc Natl Acad Sci USA 114:2699\u20132704. https:\/\/doi.org\/10.1073\/pnas.1616152114","journal-title":"Proc Natl Acad Sci USA"},{"key":"5419_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105507","volume":"159","author":"M Cosden","year":"2021","unstructured":"Cosden M, Jinn S, Yao L et al (2021) A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. Neurobiol Dis 159:105507. https:\/\/doi.org\/10.1016\/j.nbd.2021.105507","journal-title":"Neurobiol Dis"},{"key":"5419_CR132","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cpdd.865","volume":"10","author":"MJ Peterschmitt","year":"2021","unstructured":"Peterschmitt MJ, Crawford NPS, Gaemers SJM et al (2021) Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers. Clin Pharmacol Drug Dev 10:86\u201398. https:\/\/doi.org\/10.1002\/cpdd.865","journal-title":"Clin Pharmacol Drug Dev"},{"key":"5419_CR133","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","volume":"22","author":"N Giladi","year":"2023","unstructured":"Giladi N, Alcalay RN, Cutter G et al (2023) Safety and efficacy of venglustat in GBA1-associated Parkinson\u2019s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 22:661\u2013671. https:\/\/doi.org\/10.1016\/S1474-4422(23)00205-3","journal-title":"Lancet Neurol"},{"key":"5419_CR134","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-016-0413-3","volume":"11","author":"BE Smid","year":"2016","unstructured":"Smid BE, Ferraz MJ, Verhoek M et al (2016) Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease Type 1 patients. Orphanet J Rare Dis 11:28. https:\/\/doi.org\/10.1186\/s13023-016-0413-3","journal-title":"Orphanet J Rare Dis"},{"key":"5419_CR135","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/ajh.24877","volume":"92","author":"PK Mistry","year":"2017","unstructured":"Mistry PK, Lukina E, Ben Turkia H et al (2017) Outcomes after 18 months of eliglustat therapy in treatment-na\u00efve adults with Gaucher disease Type 1: The phase 3 ENGAGE trial. Am J Hematol 92:1170\u20131176. https:\/\/doi.org\/10.1002\/ajh.24877","journal-title":"Am J Hematol"},{"key":"5419_CR136","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13023-017-0565-9","volume":"12","author":"N Gu\u00e9rard","year":"2017","unstructured":"Gu\u00e9rard N, Morand O, Dingemanse J (2017) Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects. Orphanet J Rare Dis 12:9. https:\/\/doi.org\/10.1186\/s13023-017-0565-9","journal-title":"Orphanet J Rare Dis"},{"key":"5419_CR137","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/cpt.790","volume":"103","author":"N Gu\u00e9rard","year":"2018","unstructured":"Gu\u00e9rard N, Oder D, Nordbeck P et al (2018) Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with fabry disease on enzyme replacement. Clin Pharmacol Ther 103:703\u2013711. https:\/\/doi.org\/10.1002\/cpt.790","journal-title":"Clin Pharmacol Ther"},{"key":"5419_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115475","volume":"256","author":"J Hu","year":"2023","unstructured":"Hu J, Zhang D, Tian K et al (2023) Small-molecule LRRK2 inhibitors for PD therapy: current achievements and future perspectives. Eur J Med Chem 256:115475. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115475","journal-title":"Eur J Med Chem"},{"key":"5419_CR139","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13024-021-00441-8","volume":"16","author":"JH Kluss","year":"2021","unstructured":"Kluss JH, Mazza MC, Li Y et al (2021) Preclinical modeling of chronic inhibition of the Parkinson\u2019s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo. Mol Neurodegener 16:17. https:\/\/doi.org\/10.1186\/s13024-021-00441-8","journal-title":"Mol Neurodegener"},{"key":"5419_CR140","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.115.227587","volume":"355","author":"MJ Fell","year":"2015","unstructured":"Fell MJ, Mirescu C, Basu K et al (2015) MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J Pharmacol Exp Ther 355:397\u2013409. https:\/\/doi.org\/10.1124\/jpet.115.227587","journal-title":"J Pharmacol Exp Ther"},{"key":"5419_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105579","volume":"162","author":"S Novello","year":"2022","unstructured":"Novello S, Mercatelli D, Albanese F et al (2022) In vivo susceptibility to energy failure Parkinsonism and LRRK2 kinase activity. Neurobiol Dis 162:105579. https:\/\/doi.org\/10.1016\/j.nbd.2021.105579","journal-title":"Neurobiol Dis"},{"key":"5419_CR142","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s40478-021-01283-7","volume":"9","author":"CF Brzozowski","year":"2021","unstructured":"Brzozowski CF, Hijaz BA, Singh V et al (2021) Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of \u03b1-synuclein. Acta Neuropathol Commun 9:180. https:\/\/doi.org\/10.1186\/s40478-021-01283-7","journal-title":"Acta Neuropathol Commun"},{"key":"5419_CR143","unstructured":"Inc DT (2018) Denali therapeutics announces first patient dosed in phase 1b study of DNL201 for Parkinson\u2019s disease. In: GlobeNewswire News Room. https:\/\/www.globenewswire.com\/news-release\/2018\/12\/10\/1664447\/0\/en\/Denali-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1b-Study-of-DNL201-for-Parkinson-s-Disease.html. Accessed 22 Dec 2023"},{"key":"5419_CR144","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","volume":"8","author":"HT Zhao","year":"2017","unstructured":"Zhao HT, John N, Delic V et al (2017) LRRK2 antisense oligonucleotides ameliorate \u03b1-synuclein inclusion formation in a Parkinson\u2019s disease mouse model. Mol Ther Nucleic Acids 8:508\u2013519. https:\/\/doi.org\/10.1016\/j.omtn.2017.08.002","journal-title":"Mol Ther Nucleic Acids"},{"key":"5419_CR145","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.stemcr.2018.11.021","volume":"12","author":"JA Korecka","year":"2018","unstructured":"Korecka JA, Talbot S, Osborn TM et al (2018) Neurite collapse and altered ER Ca2+ control in human Parkinson disease patient iPSC-derived neurons with LRRK2 G2019S mutation. Stem Cell Reports 12:29\u201341. https:\/\/doi.org\/10.1016\/j.stemcr.2018.11.021","journal-title":"Stem Cell Reports"},{"key":"5419_CR146","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1124\/jpet.118.255695","volume":"369","author":"PA Howson","year":"2019","unstructured":"Howson PA, Johnston TH, Ravenscroft P et al (2019) Beneficial effects of trehalose on striatal dopaminergic deficits in rodent and primate models of synucleinopathy in Parkinson\u2019s disease. J Pharmacol Exp Ther 369:364\u2013374. https:\/\/doi.org\/10.1124\/jpet.118.255695","journal-title":"J Pharmacol Exp Ther"},{"key":"5419_CR147","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1007\/s12035-015-9173-7","volume":"53","author":"Q He","year":"2016","unstructured":"He Q, Koprich JB, Wang Y et al (2016) Treatment with trehalose prevents behavioral and neurochemical deficits produced in an AAV \u03b1-synuclein rat model of Parkinson\u2019s disease. Mol Neurobiol 53:2258\u20132268. https:\/\/doi.org\/10.1007\/s12035-015-9173-7","journal-title":"Mol Neurobiol"},{"key":"5419_CR148","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/s0278-6915(02)00011-x","volume":"40","author":"AB Richards","year":"2002","unstructured":"Richards AB, Krakowka S, Dexter LB et al (2002) Trehalose: a review of properties, history of use and human tolerance, and results of multiple safety studies. Food Chem Toxicol 40:871\u2013898. https:\/\/doi.org\/10.1016\/s0278-6915(02)00011-x","journal-title":"Food Chem Toxicol"},{"key":"5419_CR149","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/15548627.2018.1535292","volume":"15","author":"P Rusmini","year":"2019","unstructured":"Rusmini P, Cortese K, Crippa V et al (2019) Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration. Autophagy 15:631\u2013651. https:\/\/doi.org\/10.1080\/15548627.2018.1535292","journal-title":"Autophagy"},{"key":"5419_CR150","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.bbrc.2015.08.076","volume":"465","author":"K Tanji","year":"2015","unstructured":"Tanji K, Miki Y, Maruyama A et al (2015) Trehalose intake induces chaperone molecules along with autophagy in a mouse model of Lewy body disease. Biochem Biophys Res Commun 465:746\u2013752. https:\/\/doi.org\/10.1016\/j.bbrc.2015.08.076","journal-title":"Biochem Biophys Res Commun"},{"key":"5419_CR151","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009313","volume":"5","author":"L Crews","year":"2010","unstructured":"Crews L, Spencer B, Desplats P et al (2010) Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One 5:e9313. https:\/\/doi.org\/10.1371\/journal.pone.0009313","journal-title":"PLoS One"},{"key":"5419_CR152","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","volume":"22","author":"ML Hebron","year":"2013","unstructured":"Hebron ML, Lonskaya I, Moussa CE-H (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinson\u2019s disease models. Hum Mol Genet 22:3315\u20133328. https:\/\/doi.org\/10.1093\/hmg\/ddt192","journal-title":"Hum Mol Genet"},{"key":"5419_CR153","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JPD-160867","volume":"6","author":"F Pagan","year":"2016","unstructured":"Pagan F, Hebron M, Valadez EH et al (2016) Nilotinib effects in Parkinson\u2019s disease and dementia with Lewy bodies. J Parkinsons Dis 6:503\u2013517. https:\/\/doi.org\/10.3233\/JPD-160867","journal-title":"J Parkinsons Dis"},{"key":"5419_CR154","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.470","volume":"7","author":"FL Pagan","year":"2019","unstructured":"Pagan FL, Hebron ML, Wilmarth B et al (2019) Pharmacokinetics and pharmacodynamics of a single dose nilotinib in individuals with Parkinson\u2019s disease. Pharmacol Res Perspect 7:e00470. https:\/\/doi.org\/10.1002\/prp2.470","journal-title":"Pharmacol Res Perspect"},{"key":"5419_CR155","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/mds.25772","volume":"29","author":"L Parnetti","year":"2014","unstructured":"Parnetti L, Chiasserini D, Persichetti E et al (2014) Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson\u2019s disease. Mov Disord 29:1019\u20131027. https:\/\/doi.org\/10.1002\/mds.25772","journal-title":"Mov Disord"},{"key":"5419_CR156","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/15548627.2018.1509818","volume":"15","author":"H Li","year":"2019","unstructured":"Li H, Ham A, Ma TC et al (2019) Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations. Autophagy 15:113\u2013130. https:\/\/doi.org\/10.1080\/15548627.2018.1509818","journal-title":"Autophagy"},{"key":"5419_CR157","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","volume":"6","author":"HJR Fernandes","year":"2016","unstructured":"Fernandes HJR, Hartfield EM, Christian HC et al (2016) ER stress and autophagic perturbations lead to elevated extracellular \u03b1-synuclein in GBA-N370S Parkinson\u2019s iPSC-derived dopamine neurons. Stem Cell Reports 6:342\u2013356. https:\/\/doi.org\/10.1016\/j.stemcr.2016.01.013","journal-title":"Stem Cell Reports"},{"key":"5419_CR158","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli JR, Xu Y-H, Sun Y et al (2011) Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146:37\u201352. https:\/\/doi.org\/10.1016\/j.cell.2011.06.001","journal-title":"Cell"},{"key":"5419_CR159","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00018-012-1061-y","volume":"70","author":"JM Bravo-San Pedro","year":"2013","unstructured":"Bravo-San Pedro JM, Niso-Santano M, G\u00f3mez-S\u00e1nchez R et al (2013) The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK\/ERK pathway. Cell Mol Life Sci 70:121\u2013136. https:\/\/doi.org\/10.1007\/s00018-012-1061-y","journal-title":"Cell Mol Life Sci"},{"key":"5419_CR160","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/hmg\/ddr481","volume":"21","author":"P G\u00f3mez-Suaga","year":"2012","unstructured":"G\u00f3mez-Suaga P, Luz\u00f3n-Toro B, Churamani D et al (2012) Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet 21:511\u2013525. https:\/\/doi.org\/10.1093\/hmg\/ddr481","journal-title":"Hum Mol Genet"},{"key":"5419_CR161","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nn.3350","volume":"16","author":"SJ Orenstein","year":"2013","unstructured":"Orenstein SJ, Kuo S-H, Tasset I et al (2013) Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 16:394\u2013406. https:\/\/doi.org\/10.1038\/nn.3350","journal-title":"Nat Neurosci"},{"key":"5419_CR162","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/15548627.2019.1603545","volume":"16","author":"PW-L Ho","year":"2020","unstructured":"Ho PW-L, Leung C-T, Liu H et al (2020) Age-dependent accumulation of oligomeric SNCA\/\u03b1-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA). Autophagy 16:347\u2013370. https:\/\/doi.org\/10.1080\/15548627.2019.1603545","journal-title":"Autophagy"},{"key":"5419_CR163","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00401-020-02145-7","volume":"139","author":"S Martin","year":"2020","unstructured":"Martin S, Smolders S, Van den Haute C et al (2020) Mutated ATP10B increases Parkinson\u2019s disease risk by compromising lysosomal glucosylceramide export. Acta Neuropathol 139:1001\u20131024. https:\/\/doi.org\/10.1007\/s00401-020-02145-7","journal-title":"Acta Neuropathol"},{"key":"5419_CR164","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/mds.21399","volume":"22","author":"C Balducci","year":"2007","unstructured":"Balducci C, Pierguidi L, Persichetti E et al (2007) Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson\u2019s disease. Mov Disord 22:1481\u20131484. https:\/\/doi.org\/10.1002\/mds.21399","journal-title":"Mov Disord"},{"key":"5419_CR165","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/mds.25495","volume":"28","author":"KD van Dijk","year":"2013","unstructured":"van Dijk KD, Persichetti E, Chiasserini D et al (2013) Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson\u2019s disease. Mov Disord 28:747\u2013754. https:\/\/doi.org\/10.1002\/mds.25495","journal-title":"Mov Disord"},{"key":"5419_CR166","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s13311-014-0294-x","volume":"11","author":"F Richter","year":"2014","unstructured":"Richter F, Fleming SM, Watson M et al (2014) A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics 11:840\u2013856. https:\/\/doi.org\/10.1007\/s13311-014-0294-x","journal-title":"Neurotherapeutics"},{"key":"5419_CR167","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1111\/bcp.14772","volume":"87","author":"JM den Heijer","year":"2021","unstructured":"den Heijer JM, Kruithof AC, van Amerongen G et al (2021) A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator. Br J Clin Pharmacol 87:3561\u20133573. https:\/\/doi.org\/10.1111\/bcp.14772","journal-title":"Br J Clin Pharmacol"},{"key":"5419_CR168","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/brain\/awac379","volume":"146","author":"R Schiffmann","year":"2023","unstructured":"Schiffmann R, Cox TM, Dedieu J-F et al (2023) Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial. Brain 146:461\u2013474. https:\/\/doi.org\/10.1093\/brain\/awac379","journal-title":"Brain"},{"key":"5419_CR169","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","volume":"27","author":"GM Pastores","year":"2005","unstructured":"Pastores GM, Barnett NL, Kolodny EH (2005) An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 27:1215\u20131227. https:\/\/doi.org\/10.1016\/j.clinthera.2005.08.004","journal-title":"Clin Ther"},{"key":"5419_CR170","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/mt.2016.53","volume":"24","author":"J Marshall","year":"2016","unstructured":"Marshall J, Sun Y, Bangari DS et al (2016) CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease. Mol Ther 24:1019\u20131029. https:\/\/doi.org\/10.1038\/mt.2016.53","journal-title":"Mol Ther"},{"key":"5419_CR171","doi-asserted-by":"publisher","first-page":"eadk6191","DOI":"10.1126\/sciadv.adk6191","volume":"9","author":"M Sanz Murillo","year":"2023","unstructured":"Sanz Murillo M, Villagran Suarez A, Dederer V et al (2023) Inhibition of Parkinson\u2019s disease-related LRRK2 by type I and type II kinase inhibitors: activity and structures. Sci Adv 9:eadk6191. https:\/\/doi.org\/10.1126\/sciadv.adk6191","journal-title":"Sci Adv"},{"key":"5419_CR172","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/mds.28490","volume":"36","author":"JM Bright","year":"2021","unstructured":"Bright JM, Carlisle HJ, Toda AMA et al (2021) Differential inhibition of LRRK2 in Parkinson\u2019s disease patient blood by a G2019S selective LRRK2 inhibitor. Mov Disord 36:1362\u20131371. https:\/\/doi.org\/10.1002\/mds.28490","journal-title":"Mov Disord"},{"key":"5419_CR173","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40478-019-0679-5","volume":"7","author":"MX Henderson","year":"2019","unstructured":"Henderson MX, Sengupta M, McGeary I et al (2019) LRRK2 inhibition does not impart protection from \u03b1-synuclein pathology and neuron death in non-transgenic mice. Acta Neuropathol Commun 7:28. https:\/\/doi.org\/10.1186\/s40478-019-0679-5","journal-title":"Acta Neuropathol Commun"},{"key":"5419_CR174","doi-asserted-by":"publisher","first-page":"6935","DOI":"10.3390\/ijms23136935","volume":"23","author":"C Ruz","year":"2022","unstructured":"Ruz C, Alcantud JL, Vives F et al (2022) Seventy-Two-Hour LRRK2 kinase activity inhibition increases lysosomal GBA expression in H4, a human neuroglioma cell line. Int J Mol Sci 23:6935. https:\/\/doi.org\/10.3390\/ijms23136935","journal-title":"Int J Mol Sci"},{"key":"5419_CR175","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/13543784.2023.2263357","volume":"32","author":"T M\u00fcller","year":"2023","unstructured":"M\u00fcller T (2023) DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson\u2019s disease. Expert Opin Investig Drugs 32:787\u2013792. https:\/\/doi.org\/10.1080\/13543784.2023.2263357","journal-title":"Expert Opin Investig Drugs"},{"key":"5419_CR176","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1523\/JNEUROSCI.3944-09.2010","volume":"30","author":"C Malagelada","year":"2010","unstructured":"Malagelada C, Jin ZH, Jackson-Lewis V et al (2010) Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson\u2019s disease. J Neurosci 30:1166\u20131175. https:\/\/doi.org\/10.1523\/JNEUROSCI.3944-09.2010","journal-title":"J Neurosci"},{"key":"5419_CR177","doi-asserted-by":"publisher","first-page":"28743","DOI":"10.3402\/pba.v5.28743","volume":"5","author":"X Bai","year":"2015","unstructured":"Bai X, Wey MC-Y, Fernandez E et al (2015) Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy. Pathobiol Aging Age Relat Dis 5:28743. https:\/\/doi.org\/10.3402\/pba.v5.28743","journal-title":"Pathobiol Aging Age Relat Dis"},{"key":"5419_CR178","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/nn.2372","volume":"12","author":"LS Tain","year":"2009","unstructured":"Tain LS, Mortiboys H, Tao RN et al (2009) Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci 12:1129\u20131135. https:\/\/doi.org\/10.1038\/nn.2372","journal-title":"Nat Neurosci"},{"key":"5419_CR179","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","volume":"78","author":"T Simuni","year":"2021","unstructured":"Simuni T, Fiske B, Merchant K et al (2021) Efficacy of nilotinib in patients with moderately advanced parkinson disease: a randomized clinical trial. JAMA Neurol 78:312\u2013320. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4725","journal-title":"JAMA Neurol"},{"key":"5419_CR180","doi-asserted-by":"publisher","first-page":"14311","DOI":"10.1523\/JNEUROSCI.0499-12.2012","volume":"32","author":"C-H Ng","year":"2012","unstructured":"Ng C-H, Guan MSH, Koh C et al (2012) AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson\u2019s disease. J Neurosci 32:14311\u201314317. https:\/\/doi.org\/10.1523\/JNEUROSCI.0499-12.2012","journal-title":"J Neurosci"},{"key":"5419_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.175","volume":"5","author":"BI P\u00e9rez-Revuelta","year":"2014","unstructured":"P\u00e9rez-Revuelta BI, Hettich MM, Ciociaro A et al (2014) Metformin lowers Ser-129 phosphorylated \u03b1-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death Dis 5:e1209. https:\/\/doi.org\/10.1038\/cddis.2014.175","journal-title":"Cell Death Dis"},{"key":"5419_CR182","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000328516","volume":"19","author":"Y Wu","year":"2011","unstructured":"Wu Y, Li X, Zhu JX et al (2011) Resveratrol-activated AMPK\/SIRT1\/autophagy in cellular models of Parkinson\u2019s disease. Neurosignals 19:163\u2013174. https:\/\/doi.org\/10.1159\/000328516","journal-title":"Neurosignals"},{"key":"5419_CR183","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2014.04.003","volume":"68","author":"MH Savolainen","year":"2014","unstructured":"Savolainen MH, Richie CT, Harvey BK et al (2014) The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse. Neurobiol Dis 68:1\u201315. https:\/\/doi.org\/10.1016\/j.nbd.2014.04.003","journal-title":"Neurobiol Dis"},{"key":"5419_CR184","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4161\/auto.8.1.18313","volume":"8","author":"J-H Lu","year":"2012","unstructured":"Lu J-H, Tan J-Q, Durairajan SSK et al (2012) Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. Autophagy 8:98\u2013108. https:\/\/doi.org\/10.4161\/auto.8.1.18313","journal-title":"Autophagy"},{"key":"5419_CR185","doi-asserted-by":"publisher","first-page":"E1817","DOI":"10.1073\/pnas.1305623110","volume":"110","author":"M Decressac","year":"2013","unstructured":"Decressac M, Mattsson B, Weikop P et al (2013) TFEB-mediated autophagy rescues midbrain dopamine neurons from \u03b1-synuclein toxicity. Proc Natl Acad Sci USA 110:E1817-1826. https:\/\/doi.org\/10.1073\/pnas.1305623110","journal-title":"Proc Natl Acad Sci USA"},{"key":"5419_CR186","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1080\/15548627.2015.1136769","volume":"12","author":"M Bourdenx","year":"2016","unstructured":"Bourdenx M, Daniel J, Genin E et al (2016) Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases. Autophagy 12:472\u2013483. https:\/\/doi.org\/10.1080\/15548627.2015.1136769","journal-title":"Autophagy"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05419-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-024-05419-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05419-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T10:08:38Z","timestamp":1725358118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-024-05419-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":186,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5419"],"URL":"https:\/\/doi.org\/10.1007\/s00018-024-05419-5","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. The authors report no declarations of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"382"}}